JP2024529763A - 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶体 - Google Patents
6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶体 Download PDFInfo
- Publication number
- JP2024529763A JP2024529763A JP2024510406A JP2024510406A JP2024529763A JP 2024529763 A JP2024529763 A JP 2024529763A JP 2024510406 A JP2024510406 A JP 2024510406A JP 2024510406 A JP2024510406 A JP 2024510406A JP 2024529763 A JP2024529763 A JP 2024529763A
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- pxrd
- pattern
- methyl
- room temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163235635P | 2021-08-20 | 2021-08-20 | |
| US63/235,635 | 2021-08-20 | ||
| PCT/US2022/040884 WO2023023322A1 (en) | 2021-08-20 | 2022-08-19 | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024529763A true JP2024529763A (ja) | 2024-08-08 |
| JP2024529763A5 JP2024529763A5 (cg-RX-API-DMAC10.html) | 2025-08-26 |
Family
ID=83283223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024510406A Pending JP2024529763A (ja) | 2021-08-20 | 2022-08-19 | 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240368130A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4387968B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024529763A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240050380A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118119614A (cg-RX-API-DMAC10.html) |
| ES (1) | ES3062193T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023023322A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024241347A1 (en) * | 2023-05-25 | 2024-11-28 | Msn Laboratories Private Limited, R&D Center | Novel polymorphs of 6-(cyclopropanecarbonylamido)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-n-(trideuteriomethyl)pyridazine-3-carboxamide |
| ES3059443A1 (es) * | 2024-09-17 | 2026-03-20 | Moehs Iberica Sl | Forma solida de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)piridazine-3-carboxilato de metilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de deucravacitinib |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019232138A1 (en) * | 2018-05-31 | 2019-12-05 | Bristol-Myers Squibb Company | Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide |
| JP2020512380A (ja) * | 2017-03-30 | 2020-04-23 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 6−(シクロプロパンカルボキサミド)−4−((2−メトキシ−3−(1−メチル−1H−1,2,4−トリアゾール−3−イル)フェニル)アミノ)−N−(メチル−d3)ピリダジン−3−カルボキサミドの結晶形態 |
| WO2020251911A1 (en) * | 2019-06-12 | 2020-12-17 | Bristol-Myers Squibb Company | Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220766T1 (hr) * | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| AU2022214313A1 (en) * | 2021-01-29 | 2023-08-17 | Bristol-Myers Squibb Company | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| CN117377667A (zh) * | 2021-03-29 | 2024-01-09 | 百时美施贵宝公司 | 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型 |
-
2022
- 2022-08-19 JP JP2024510406A patent/JP2024529763A/ja active Pending
- 2022-08-19 ES ES22769445T patent/ES3062193T3/es active Active
- 2022-08-19 KR KR1020247008835A patent/KR20240050380A/ko active Pending
- 2022-08-19 CN CN202280068807.1A patent/CN118119614A/zh active Pending
- 2022-08-19 WO PCT/US2022/040884 patent/WO2023023322A1/en not_active Ceased
- 2022-08-19 US US18/684,747 patent/US20240368130A1/en active Pending
- 2022-08-19 EP EP22769445.2A patent/EP4387968B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020512380A (ja) * | 2017-03-30 | 2020-04-23 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 6−(シクロプロパンカルボキサミド)−4−((2−メトキシ−3−(1−メチル−1H−1,2,4−トリアゾール−3−イル)フェニル)アミノ)−N−(メチル−d3)ピリダジン−3−カルボキサミドの結晶形態 |
| WO2019232138A1 (en) * | 2018-05-31 | 2019-12-05 | Bristol-Myers Squibb Company | Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide |
| WO2020251911A1 (en) * | 2019-06-12 | 2020-12-17 | Bristol-Myers Squibb Company | Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide |
Non-Patent Citations (4)
| Title |
|---|
| C.G.WERMUTH編, 最新 創薬化学 下巻, JPN6014029314, 1999, pages 347 - 365, ISSN: 0005886040 * |
| 厚生省医薬安全局審査管理課長: "医薬品の残留溶媒ガイドラインについて", 医薬審, JPN6014031669, 1998, ISSN: 0005886038 * |
| 平山 令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005886037 * |
| 芦澤一英, 医薬品の多形現象と晶析の化学, JPN6015027444, 2002, pages 273 - 278, ISSN: 0005886039 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES3062193T3 (en) | 2026-04-09 |
| CN118119614A (zh) | 2024-05-31 |
| KR20240050380A (ko) | 2024-04-18 |
| EP4387968B1 (en) | 2025-11-12 |
| WO2023023322A1 (en) | 2023-02-23 |
| US20240368130A1 (en) | 2024-11-07 |
| EP4387968A1 (en) | 2024-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12545665B2 (en) | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide | |
| US11613529B2 (en) | Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-D3) pyridazine-3-carboxamide | |
| US12129245B2 (en) | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3) pyridazine-3-carboxamide | |
| US20240190845A1 (en) | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide | |
| EP4387968B1 (en) | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide | |
| WO2025106462A1 (en) | 2-(4-(2-(7, 8-dimethyl-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-3-isopropyl-1h-indol-5-yl)piperidin-1-yl)acetamide salt and crystalline forms thereof | |
| EA044397B1 (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-(ЦИКЛОПРОПАНКАРБОКСАМИДО)-4-((2-МЕТОКСИ-3-(1-МЕТИЛ-1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ФЕНИЛ)АМИНО)-N-(МЕТИЛ-d3)ПИРИДАЗИН-3-КАРБОКСАМИДА |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20241115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250818 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250818 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260616 |